An exploratory study of the NAVIGATOR trial for PDGFRA-mutant GIST showed that mutant ctDNA was detected in 63% of patients, and in this same population, the median sum of target lesions was 18.2 cm, suggesting that ctDNA detection might be potentially limited by the tumor burden [59]. Here, PDGFRA is linked to neoplasm.